Transfus Apher Sci
-
This report describes the evolution of Cord Blood (CB) hematopoietic stem cell transplants (HSCTs) in Europe over time and its current status. There were 687 patients with a first CB HSCT and a total of 763 allogeneic CB HSCT but no autologous CB HSCT reported in the year 2008. The 687 first transplants correspond to 6% of the total 11,408 allogeneic HSCT. ⋯ Main indications for the 639 unrelated first CB HSCT were acute leukaemia (337;53%), non-malignant disorders (115;18%) and lymphoproliferative disorders (53; 8%). 159 teams out of the 368 teams performing allogeneic HSCT (43%) reported 1 to 37 CB HSCT (median 3). There were significant differences in use of CB in the participating European countries with a median CB transplant number of 6.5 (range 1-207), transplant rate (number of CB HSCT/10 million inhabitants) of 6.3 (range 0.1-234.6) and a proportion of CB amongst allogeneic HSCT from 0.7% to 18.2% (median 5.4%). These data document the established role of CB HSCT in Europe but point to significant differences in its use.
-
The effects of blood donation on iron status in donors without iron supplementation were studied. Analysing interactions between donations and iron status markers may predict these effects. ⋯ Adjusting the donation intervals is a way to prevent iron deficiency in blood donors.
-
In order to further improve blood safety, mini-pool (MP) nucleic acid testing (NAT) was implemented to screen samples negative for hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (anti-HCV), anti-human immunodeficiency virus (anti-HIV), syphilis (anti-Treponemal antibody) and with normal ALT. ⋯ MP NAT identified two HBsAg negative donors with presumed occult infection but no HIV or HCV seronegative/NAT positive (yield) donors. The HBV yield rate of 1 in 20,650 (95%CI - 1 in 5663 to 1 in 75,303) is comparatively high, exceeds the predicted rate based on previous modeling for the population and demonstrates the incremental blood safety value of NAT in countries where HBV is highly epidemic. The low viral load of the two yield samples underscores the importance of optimizing the sensitivity of the HBV NAT assay selected for screening.
-
Multicenter Study
Does the preoperative iron status predict transfusion requirement of orthopedic patients?
In patients scheduled for major orthopedic surgery, the presence of anemia before surgery can preclude the transfusion requirements. Iron deficiency anemia is believed to be a major cause of anemia, especially in the elderly. The importance of screening patients undergoing major orthopedic surgery in Norway for anemia and iron deficiency has not been investigated. The aim of the present study was to investigate if preoperative testing of iron status could predict transfusion requirement related to major elective orthopedic surgery. ⋯ There was no correlation between the iron status before surgery and the need for transfusion during and after surgery, although anemia before surgery was a predictor for the need for transfusion. Based in our limited study we could not recommend iron status screening before surgery. However further studies are needed to truly establish the incidence and the underlying etiology, in order to reduce the transfusion requirements.